Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients

Hematol Oncol. 2021 Dec;39(5):715-720. doi: 10.1002/hon.2908. Epub 2021 Aug 16.

Barbora Weinbergerova^{1

2}, Jiri Mayer^{1

2}, Tomas Kabut^{1

2}, Stepan Hrabovsky^{1

2}, Jirina Prochazkova^{1

2}, Zdenek Kral^{1

2}, Vladimir Herout^{3

4}, Rita Pacasova^{5

6}, Lenka Zdrazilova-Dubska⁷, Petr Husa^{8

9}, Petr Bednar^{10

11}, Daniel Ruzek^{10

12}, Martina Lengerova^{1

2}

¹ Department of Internal Medicine-Hematology and Oncology, Masaryk University, Brno, Czech Republic.
² Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
³ Department of Respiratory Diseases, Masaryk University, Brno, Czech Republic.
⁴ Department of Respiratory Diseases, University Hospital Brno, Brno, Czech Republic.
⁵ Transfusion and Tissue Department, Masaryk University, Brno, Czech Republic.
⁶ Transfusion and Tissue Department, University Hospital Brno, Brno, Czech Republic.
⁷ Department of Clinical Microbiology and Immunology, University Hospital Brno, Brno, Czech Republic.
⁸ Department of Infectious Diseases, Masaryk University, Brno, Czech Republic.
⁹ Department of Infectious Diseases, University Hospital Brno, Brno, Czech Republic.
¹⁰ Veterinary Research Institute, Brno, Czech Republic.
¹¹ Faculty of Science, University of South Bohemia, Ceske Budejovice, Czech Republic.
¹² Institute of Parasitology, Biology Centre of the Czech Academy of Sciences, Ceske Budejovice, Czech Republic.

No abstract available

Publication types